You just read:

Five-year outcomes results from European 'PlanB' study show that breast cancer patients with low Oncotype DX® Recurrence Score® results can be spared chemotherapy despite having high-risk disease by traditional measures

News provided by

Genomic Health, Inc.

11 Mar, 2016, 10:05 GMT